GC Green Cross Presents Achievements of 'mRNA-LNP Platform' at Domestic and International Conferences

GC Green Cross announced on November 26 that it recently presented major research findings on its "Next-Generation mRNA-LNP (messenger RNA-lipid nanoparticle) Platform for Innovative Drug Development" at domestic and international conferences.

In its mRNA platform research, GC Green Cross applied its proprietary AI-based codon optimization technology (codons are segments in the mRNA structure that produce proteins) along with patented UTR (untranslated region, which regulates expression stability before and after the codon) technology, significantly enhancing both the protein expression levels and the duration of expression of mRNA. Additionally, its independently developed LNP platform demonstrated improved cell-specific delivery efficiency while maintaining a low toxicity profile.

Exterior view of GC Green Cross headquarters in Yongin, Gyeonggi Province. GC Green Cross

Based on this mRNA-LNP platform, GC Green Cross is advancing the development of various new drugs. In practice, the company is exploring the platform's applicability not only for vaccines against infectious diseases such as COVID-19 and influenza, but also for cancer vaccines, treatments for rare diseases, gene editing, and cell therapies such as CAR-T (chimeric antigen receptor T-cell) therapies.

Notably, research on cancer vaccines utilizing GC Green Cross's LNP showed that it induced a stronger antigen-specific CD8+ T cell response compared to benchmark LNPs, and significantly reduced tumor size in animal models. CD8+ T cells are key immune cells responsible for destroying cancer cells.

Furthermore, a CAR-T cell therapy candidate developed using the company’s proprietary mRNA technology demonstrated outstanding results in ex vivo evaluations, eliminating up to 99% of B cells. B cell elimination is a major indicator of CAR-T’s anticancer function, as the effectiveness of removing abnormal B cells is directly linked to therapeutic efficacy. The company stated that it plans to expand its development scope to include treatments for cancer and autoimmune diseases.

Ma Sung Hoon, Head of Medicine Discovery & Development (MDD) at GC Green Cross, said, “The mRNA-LNP platform is expanding beyond vaccines into a wide range of fields,” adding, “GC Green Cross will continue to develop innovative therapeutics based on its accumulated research achievements.”

Meanwhile, throughout November, GC Green Cross participated in and presented at the 2025 KSGCT Annual Conference, the 2025 mRNA Healthcare Conference, and the RNA-based Therapeutics and Vaccines Summit Asia.

This content was produced with the assistance of AI translation services.